U.S. Markets open in 5 hrs 43 mins

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio


Swiss drugmaker Roche Group announced it would buy Seragon Pharmaceuticals for $1.7 billion. It's the latest in a series of acquisitions for Roche, which bought Genia Technologies in June for $350 million and IQuum in May for $450 million. The Deal correspondent Andrew Bulkeley explains how Seragon's portfolio, which includes a focus on treatments for breast cancer, will impact Roche and its subsidiary Genentech going forward. Also, as the company widens its offerings of cancer treatments, Bulkeley reveals what other holes it may have in its portfolio and what other acquisitions it may make down the road.